49 results on '"Neggers, Sebastian J C M M"'
Search Results
2. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.
- Author
-
Basu, Reetobrata, Kulkarni, Prateek, Swegan, Deborah, Duran-Ortiz, Silvana, Ahmad, Arshad, Caggiano, Lydia J., Davis, Emily, Walsh, Christopher, Brenya, Edward, Koshal, Adeel, Brody, Rich, Sandbhor, Uday, Neggers, Sebastian J. C. M. M., and Kopchick, John J.
- Subjects
SOMATOTROPIN receptors ,PITUITARY dwarfism ,HORMONE antagonists ,PANCREATIC cancer ,TREATMENT effectiveness ,LABORATORY mice ,GEMCITABINE - Abstract
Chemotherapy treatment against pancreatic ductal adenocarcinoma (PDAC) is thwarted by tumoral activation of multiple therapy resistance pathways. The growth hormone (GH)–GH receptor (GHR) pair is a covert driver of multimodal therapy resistance in cancer and is overexpressed in PDAC tumors, yet the therapeutic potential of targeting the same has not been explored. Here, we report that GHR expression is a negative prognostic factor in patients with PDAC. Combinations of gemcitabine with different GHR antagonists (GHRAs) markedly improve therapeutic outcomes in nude mice xenografts. Employing cultured cells, mouse xenografts, and analyses of the human PDAC transcriptome, we identified that attenuation of the multidrug transporter and epithelial-to-mesenchymal transition programs in the tumors underlie the observed augmentation of chemotherapy efficacy by GHRAs. Moreover, in human PDAC patients, GHR expression strongly correlates with a gene signature of tumor promotion and immune evasion, which corroborate with that in syngeneic tumors in wild-type vs. GH transgenic mice. Overall, we found that GH action in PDAC promoted a therapy-refractory gene signature in vivo, which can be effectively attenuated by GHR antagonism. Our results collectively present a proof of concept toward considering GHR antagonists to improve chemotherapeutic outcomes in the highly chemoresistant PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Presence and utility of electrocardiographic abnormalities in long-term childhood cancer survivors.
- Author
-
de Baat, Esmée C., Merkx, Remy, Leerink, Jan M., Boerhout, Coen, van der Pal, Heleen J. H., van Dalen, Elvira C., Loonen, Jacqueline, Bresters, Dorine, van Dulmen-den Broeder, Eline, van der Heiden-van der Loo, Margriet, van den Heuvel, Marry M., Kok, Judith L., Louwerens, Marloes, Neggers, Sebastian J. C. M. M., Ronckers, Cecline M., Teepen, Jop C., Tissing, Wim J. E., de Vries, Andrica C., Kapusta, Livia, and Kremer, Leontien C. M.
- Subjects
HEART failure ,CHILDHOOD cancer ,CANCER survivors ,MEDICAL ethics - Published
- 2024
- Full Text
- View/download PDF
4. [18F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors.
- Author
-
Pruis, Ilanah J., Verburg, Frederik A., Balvers, Rutger K., Harteveld, Anita A., Feelders, Richard A., Vernooij, Meike W., Smits, Marion, Neggers, Sebastian J. C. M. M., and Veldhuijzen van Zanten, Sophie E. M.
- Published
- 2024
- Full Text
- View/download PDF
5. The cumulative burden of self‐reported, clinically relevant outcomes in long‐term childhood cancer survivors and implications for survivorship care: A DCCSS LATER study.
- Author
-
Streefkerk, Nina, Teepen, Jop C., Feijen, Elizabeth A. M., Jóźwiak, Katarzyna, van der Pal, Helena J. H., Ronckers, Cecile M., De Vries, Andrica C. H., Van der Heiden‐van Der Loo, Margriet, Hollema, Nynke, van den Berg, Marleen, Loonen, Jacqueline, Grootenhuis, Martha A., Bresters, Dorine, Versluys, A. Brigitta, van Dulmen‐den Broeder, Eline, van den Heuvel‐Eibrink, Marry M., van Leeuwen, Flora E., Neggers, Sebastian J. C. M. M., Van Santen, Hanneke M., and Hawkins, Mike
- Subjects
CHILDHOOD cancer ,CANCER survivors ,MISSING data (Statistics) ,TUMOR treatment ,CONFIDENCE intervals - Abstract
Background: The aim of this study is to evaluate how cumulative burden of clinically relevant, self‐reported outcomes in childhood cancer survivors (CCSs) compares to a sibling control group and to explore how the burden corresponds to levels of care proposed by existing risk stratifications. Methods: The authors invited 5925 5‐year survivors from the Dutch Childhood Cancer Survivor Study (DCCSS LATER) cohort and their 1066 siblings to complete a questionnaire on health outcomes. Health outcomes were validated by self‐reported medication use or medical record review. Missing data on clinically relevant outcomes in CCSs for whom no questionnaire data were available were imputed with predictive mean matching. We calculated the mean cumulative count (MCC) for clinically relevant outcomes. Furthermore, we calculated 30‐year MCC for groups of CCSs based on primary cancer diagnosis and treatment, ranked 30‐year MCC, and compared the ranking to levels of care according to existing risk stratifications. Results: At median 18.5 years after 5‐year survival, 46% of CCSs had at least one clinically relevant outcome. CCSs experienced 2.8 times more health conditions than siblings (30‐year MCC = 0.79; 95% confidence interval [CI], 0.74–0.85 vs. 30‐year MCC = 0.29; 95% CI, 0.25–0.34). CCSs' burden of clinically relevant outcomes consisted mainly of endocrine and vascular conditions and varied by primary cancer type. The ranking of the 30‐year MCC often did not correspond with levels of care in existing risk stratifications. Conclusions: CCSs experience a high cumulative burden of clinically relevant outcomes that was not completely reflected by current risk stratifications. Choices for survivorship care should extend beyond primary tumor and treatment parameters, and should consider also including CCSs' current morbidity. Survivors of childhood cancer experience a high cumulative burden of clinically relevant outcomes. Choices for survivorship care should extend beyond primary tumor and treatment parameters and should also consider including the current morbidity of childhood cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Leptin Increase During Dexamethasone and Its Association With Hunger and Fat in Pediatric Acute Lymphoblastic Leukemia.
- Author
-
van Hulst, Annelienke M., Verwaaijen, Emma J., van den Berg, Sjoerd A. A., van Litsenburg, Raphaële R. L., Grootenhuis, Martha A., Fiocco, Marta, Neggers, Sebastian J. C. M. M., van den Heuvel-Eibrink, Marry M., and van den Akker, Erica L. T.
- Subjects
LEPTIN ,DEXAMETHASONE ,LYMPHOBLASTIC leukemia - Abstract
Context: During treatment, children with acute lymphoblastic leukemia (ALL) receive high doses dexamethasone, which induce acute side effects. Objective: To determine the influence of a 5-day dexamethasone course on changes in leptin, fat mass, BMI, hunger, sleep, and fatigue and to explore associations between these changes. Methods: Pediatric ALL patients were included during maintenance treatment. Data were collected before (T1) and after (T2) a 5-day dexamethasone course (6 mg/m2/day). At both time points, BMI, fat mass (bioelectrical impedance analysis), and leptin were assessed, as well as parent-reported questionnaires regarding hunger, fatigue, and sleep problems. Changes between T1 and T2 were assessed using paired tests. Correlation coefficients were calculated to assess associations between these changes (Delta scores: T2-T1). Univariable regression models were estimated to study associations between covariates and elevated leptin. Results: We included 105 children, with median age 5.4 years (range, 3.0-18.8). Leptin and fat mass, as well as hunger scores, fatigue, and sleep deteriorated after 5 days of dexamethasone (P < .001), in contrast to BMI (P = .12). No correlations between delta leptin and delta fat mass, BMI, hunger, fatigue, or sleep were found. Elevated leptin on T1 was associated with older age (odds ratio [OR] 1.51; 95% CI, 1.28-1.77), higher fat mass (OR 1.19; 95% CI, 1.07-1.33), and earlier maintenance week (OR 0.96; 95% CI, 0.92-0.99). Conclusion: Five days of high-dose dexamethasone treatment led to direct and significant changes in leptin, hunger scores, and fat mass. Since children with ALL are at increased risk for metabolic adverse events, understanding underlying mechanisms is important, and a dexamethasoneinduced state of acute leptin resistance might play a role. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin.
- Author
-
Nijenhuis-Noort, Eline C., Berk, Kirsten A., Neggers, Sebastian J. C. M. M., and van der Lely, Aart J.
- Subjects
SOMATOTROPIN ,TYPE 1 diabetes ,TYPE 2 diabetes ,INSULIN ,CIRRHOSIS of the liver - Abstract
This review intends to provide the reader with a practical overview of several (patho)physiological conditions in which knowledge of the interplay between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin is important. This might help treating physicians in making the right decisions on how to intervene and improve metabolism for the benefit of patients, and to understand why and how metabolism responds in their specific cases. We will specifically address the interplay between GH, IGF-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Psychopathology in Acromegaly—Real and Perceived.
- Author
-
Pivonello, Rosario, Neggers, Sebastian J. C. M. M., and Imran, Syed Ali
- Subjects
PATHOLOGICAL psychology ,ACROMEGALY ,SEXUAL dysfunction - Abstract
Acromegaly is a chronic condition caused by the excessive production of growth hormone and is characterized by progressive morphological and systemic complications, as well as increased prevalence of psychopathologies, which markedly affect patients’ quality of life. The advancing multimodal therapies, while significantly improving the morbidity and mortality, have limited impact on psychopathologies, which often persist despite disease remission. The most common psychopathologies in acromegaly include depression, anxiety and affective disorders, together with sexual dysfunction, which may be considered as either a consequence or potentially even a contributory factor to these psychopathologies. Approximately one-third of patients with acromegaly manifest depression, whereas two-thirds of patients display anxiety, with both conditions tending to be more prevalent and severe in younger patients with shorter duration of disease. Apparently, a major impact of psychological discomfort in women compared with men appears to be the fact that women tend to internalize whereas men tend to externalize their distress. Personality disorders also commonly associated with acromegaly, especially due to body image suffering, are linked to sexual dysfunction, which seems to affect women more than men. In summary, psychopathology in acromegaly is a major determinant of the quality of life and a complex array of psychological abnormalities are associated with acromegaly. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Long-term safety of growth hormone replacement therapy in survivors of cancer and tumors of the pituitary region.
- Author
-
Bolier, Melissa, van der Lelij, Aart-Jan, Janssens, Geert O., van den Heuvel-Eibrink, Marry M., and Neggers, Sebastian J. C. M. M.
- Subjects
SOMATOTROPIN ,PITUITARY tumors ,CANCER survivors ,HORMONE therapy ,ACROMEGALY ,PITUITARY cancer - Abstract
Growth hormone deficiency (GHD) is a common complication in survivors of cancer and patients with tumors of the pituitary region. Growth hormone replacement therapy (GHT) has proven beneficial effects, including increased growth velocity, positive effects on body composition and skeletal integrity, and increased quality of life. However, due to known pro-proliferative, angiogenic, and anti-apoptotic properties of growth hormone, there are still some concerns about the safety of GHT in survivors. This narrative review aims to provide an overview of the long-term sequelae, and subsequently long-term safety, of GHT in survivors of (childhood) cancer and patients with tumors of the pituitary region. We identified predominantly reassuring results regarding the safety of survivors with GHT, although we must take into account the shortcomings of some studies and limited information on adult cancer survivors. Besides the already increased risk for second neoplasms, recurrences, or mortality in survivors due to host-, disease-, and treatmentrelated factors, we could not identify an increased risk due to GHT in particular. Therefore, we support the consensus that GHT can be considered in survivors after careful individual risk/benefit analysis and in open discussion with the patients and their families, taking into account the known morbidity of untreated GHD in cancer survivors and the positive effects of GHT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Self-reported outcomes on oral health and oral health-related quality of life in long-term childhood cancer survivors—A DCCSS-LATER 2 Study.
- Author
-
Stolze, Juliette, Raber-Durlacher, Judith E., Loonen, Jacqueline J., Teepen, Jop C., Ronckers, Cécile M., Tissing, Wim J. E., de Vries, Andrica C. H., Neggers, Sebastian J. C. M. M., Dulmen-den Broeder, Eline, Heuvel-Eibrink, Marry M., van der Pal, Helena J. H., Versluys, A. Birgitta, Heiden-van der Loo, Margriet, Louwerens, Marloes, Kremer, Leontien C. M., Bresters, Dorine, Brand, Henk S., Grootenhuis, Martha, van Leeuwen, Flora, and van der Steeg, Lideke
- Abstract
Purpose: The present study aimed to determine the prevalence of self-reported oral problems and the oral health–related quality of life (OHRQoL) in childhood cancer survivors (CCS). Methods: Patient and treatment characteristics of CCS have been collected in a cross-sectional study, part of the multidisciplinary DCCSS-LATER 2 Study. To assess self-reported oral health problems and dental problems, CCS filled out the ‘Toegepast-Natuurwetenschappelijk Onderzoek’ (TNO) oral health questionnaire. OHRQoL was assessed by the Dutch version of the Oral Health Impact Profile-14 (OHIP-14). Prevalences were compared with two comparison groups from the literature. Univariable and multivariable analyses were performed. Results: A total of 249 CCS participated in our study. The OHIP-14 total score had a mean value of 1.94 (sd 4.39), with a median score of 0 (range 0–29). The oral problems ‘oral blisters/aphthae’ (25.9%) and ‘bad odor/halitosis’ (23.3%) were significantly more often reported in CCS than in comparison groups (12% and 12%, respectively). The OHIP-14 score was significantly correlated with the number of self-reported oral health problems (r =.333, p<0.0005) and dental problems (r =.392, p <0.0005). In multivariable analysis, CCS with a shorter time since diagnosis (10-19 years vs. ≥30 years) had a 1.47-fold higher risk of ≥1 oral health problem. Conclusion: Though the perceived oral health is relatively good, oral complications following childhood cancer treatment are prevalent in CCS. This underlines that attention to impaired oral health and awareness on this topic is mandatory and regular visits to the dentist should be a part of long-term follow-up care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors.
- Author
-
Gatto, Federico, Feelders, Richard A., van Koetsveld, Peter M., Dogan, Fadime, Neggers, Sebastian J. C. M. M., van der Lelij, Aart-Jan, Amarù, Jessica, Ferone, Diego, and Hofland, Leo J.
- Subjects
OCTREOTIDE acetate ,PITUITARY tumors ,SOMATOSTATIN receptors - Abstract
Context: Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, eg, octreotide (OCT). Objective: This was a head-to-head comparison between OCT and CAB in inhibiting growth hormone (GH) secretion in primary cultures of GH and GH/prolactin (PRL)-secreting tumors; we also investigated the role of somatostatin (SST) and dopamine type 2 (D2R) receptor expression. Methods: We evaluated the antisecretory effect of OCT and CAB, together with receptor mRNA expression, in 23 tumor cultures obtained from acromegaly patients referred to the Erasmus Medical Center (Rotterdam, The Netherlands). GH concentrations in cell culture media were determined after 72-hour OCT and CAB treatment (10 nM). Results: OCT showed a slightly higher efficacy compared with CAB (GH decrease −39.5% vs −32.5%, P=0.079). The effect of the 2 drugs was superimposable in GH/PRL co-secreting tumors (−42.1% vs −44.8%), where SST
1 and D2R had a higher expression compared with the pure GH secreting tumors (P=0.020 and P=0.026). OCT was more effective than CAB in 8/23 cultures, while CAB was more effective than OCT in 3/23 (CAB+ group). In CAB+ tumors, SST1 expression was higher compared with the other groups (P=0.034). At receiver operating characteristic (ROC) curve analysis, SST1 and D2R discriminated between GH and GH/PRL co-secretion (AUC 0.856, P=0.013; AUC 0.822, P=0.024). SST1 was the best predictor of CAB response (≥50% GH reduction, AUC 0.913, P=0.006; 80% sensitivity, 94% specificity). Conclusion: OCT is 5% to 10% more effective than CAB in vitro. SST1 mRNA expression can represent a reliable marker of GH/PRL co-secreting tumors showing a preferential response to CAB treatment. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
12. Clinical evaluation of late outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER 2 study.
- Author
-
Feijen, Elizabeth A. M., Teepen, Jop C., van Dulmen‐den Broeder, Eline, van den Heuvel‐Eibrink, Marry M., van der Heiden‐van der Loo, Margriet, van der Pal, Helena J. H., de Vries, Andrica C. H., Louwerens, Marloes, Bresters, Dorine, Versluys, Birgitta, de Ridder, Hanneke, Veening, Margreet, van Leeuwen, Flora E., Grootenhuis, Martha, Maurice‐Stam, Heleen, van Santen, Hanneke M., Neggers, Sebastian J. C. M. M., Pluijm, Saskia, den Hartogh, Jaap, and Ronckers, Cécile M.
- Published
- 2023
- Full Text
- View/download PDF
13. Experiences of Female Childhood Cancer Patients and Survivors Regarding Information and Counselling on Gonadotoxicity Risk and Fertility Preservation at Diagnosis: A Systematic Review.
- Author
-
Clasen, Nikita H. Z., van der Perk, M. E. Madeleine, Neggers, Sebastian J. C. M. M., Bos, Annelies M. E., and van den Heuvel-Eibrink, Marry M.
- Subjects
CANCER patient psychology ,ONLINE information services ,COUNSELING ,MEDICAL information storage & retrieval systems ,SYSTEMATIC reviews ,PATIENT satisfaction ,TUMORS in children ,PATIENTS' attitudes ,RISK assessment ,INFERTILITY ,PSYCHOLOGY of women ,HEALTH ,INFORMATION resources ,OVARIAN diseases ,FERTILITY preservation ,COMMUNICATION ,MEDLINE ,PATIENT-professional relations ,CANCER patient medical care ,DISEASE risk factors ,DISEASE complications - Abstract
Simple Summary: Due to the significant increase in overall survival rates of childhood cancer, more awareness has been raised for the long-term consequences of treatment, including infertility. Currently, patients and their families are offered information regarding the risk of gonadal damage by paediatric oncologists and fertility counselling by fertility specialists regarding fertility preservation. However, the experiences of childhood cancer patients with oncofertility care are underreported. The available evidence reported in this review shows that female patients and survivors are variably satisfied with fertility information and report challenges in communication. They prefer to receive general information at diagnosis and detailed information later. Regrets are reported after refusal of fertility preservation. Patients and survivors are concerned about future children's health, effect on relationships and lack of control over fertility. With the results from this review, (international) standards for information for paediatric cancer patients and families may be developed to improve fertility information and counselling for current and future childhood cancer patients and survivors. Background: Childhood cancer patients and their families are increasingly offered oncofertility care including information regarding their risk of gonadal damage by paediatric oncologists, fertility counselling by fertility specialists and fertility preservation options. However, experiences regarding oncofertility care are underreported. We aimed to summarize the available evidence of experiences of female childhood cancer patients and survivors regarding oncofertility care. Methods: Manuscripts were systematically identified using the PubMed and Embase database. From, respectively, 1256 and 3857 manuscripts, 7 articles were included and assessed, including risk of bias assessment. Outcome measures included data describing experiences of female childhood cancer patients and survivors, regarding fertility information, counselling and/or preservation. Results: Female patients and survivors are variably satisfied with fertility information, report challenges in communication with healthcare professionals and prefer to receive general information at diagnosis and detailed fertility information later. Regrets after fertility counselling are underreported, but are associated with refusing fertility preservation. Lastly, regardless of counselling, female patients and survivors report fertility concerns about their future children's health and effect on relationships. Conclusion: Currently, the satisfaction with oncofertility care varies and female patients or survivors report regrets and concerns regardless of receiving fertility information or counselling. These results may help to improve the content of fertility information, communication skills of healthcare professionals and timing of counselling. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Questionnaire‐ and linkage‐based outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER study part 1.
- Author
-
Teepen, Jop C., Kok, Judith L., Feijen, Elizabeth A. M., Loonen, Jacqueline J., van den Heuvel‐Eibrink, Marry M., van der Pal, Helena J., Tissing, Wim J. E., Bresters, Dorine, Versluys, Birgitta, Grootenhuis, Martha A., Louwerens, Marloes, Neggers, Sebastian J. C. M. M., van Santen, Hanneke M., de Vries, Andrica, Janssens, Geert O., den Hartogh, Jaap G., van Leeuwen, Flora E., Hollema, Nynke, Streefkerk, Nina, and Kilsdonk, Ellen
- Subjects
CHILDHOOD cancer ,CANCER survivors ,MEDICAL registries ,MEDICAL care use ,PEDIATRIC oncology ,CANCER fatigue - Abstract
Background: Childhood cancer survivors are at risk for developing long‐term adverse health outcomes. To identify the risk of and risk factors for specific health outcomes, well‐established cohorts are needed with detailed information on childhood cancer diagnosis, treatment, and health outcomes. We describe the design, methodology, characteristics, and data availability of the Dutch Childhood Cancer Survivor Study LATER cohort (1963–2001) part 1; questionnaire and linkage studies. Methods: The LATER cohort includes 5‐year childhood cancer survivors, diagnosed in the period 1963–2001, and before the age of 18 in any of the seven former pediatric oncology centers in the Netherlands. Information on health outcomes from survivors and invited siblings of survivors was collected by questionnaires and linkages to medical registries. Results: In total, 6165 survivors were included in the LATER cohort. Extensive data on diagnosis and treatment have been collected. Information on a variety of health outcomes has been ascertained by the LATER questionnaire study and linkages with several registries for subsequent tumors, health care use, and hospitalizations. Conclusion: Research with data of the LATER cohort will provide new insights into risks of and risk factors for long‐term health outcomes. This can enhance risk stratification for childhood cancer survivors and inform surveillance guidelines and development of interventions to prevent (the impact of) long‐term adverse health outcomes. The data collected will be a solid baseline foundation for future follow‐up studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors.
- Author
-
Iersel, Laura van, Mulder, Renee L, Denzer, Christian, Cohen, Laurie E, Spoudeas, Helen A, Meacham, Lillian R, Sugden, Elaine, Meeteren, Antoinette Y N Schouten-van, Hoving, Eelco W, Packer, Roger J, Armstrong, Gregory T, Mostoufi-Moab, Sogol, Stades, Aline M, Vuurden, Dannis van, Janssens, Geert O, Thomas-Teinturier, Cécile, Murray, Robert D, Iorgi, Natascia Di, Neggers, Sebastian J C M M, and Thompson, Joel
- Subjects
CANCER survivors ,CHILDHOOD cancer ,HYPOTHALAMIC-pituitary-adrenal axis - Abstract
Endocrine disorders in survivors of childhood, adolescent, and young adult (CAYA) cancers are associated with substantial adverse physical and psychosocial effects. To improve appropriate and timely endocrine screening and referral to a specialist, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) aims to develop evidence and expert consensus-based guidelines for healthcare providers that harmonize recommendations for surveillance of endocrine disorders in CAYA cancer survivors. Existing IGHG surveillance recommendations for premature ovarian insufficiency, gonadotoxicity in males, fertility preservation, and thyroid cancer are summarized. For hypothalamic-pituitary (HP) dysfunction, new surveillance recommendations were formulated by a guideline panel consisting of 42 interdisciplinary international experts. A systematic literature search was performed in MEDLINE (through PubMed) for clinically relevant questions concerning HP dysfunction. Literature was screened for eligibility. Recommendations were formulated by drawing conclusions from quality assessment of all evidence, considering the potential benefits of early detection and appropriate management. Healthcare providers should be aware that CAYA cancer survivors have an increased risk for endocrine disorders, including HP dysfunction. Regular surveillance with clinical history, anthropomorphic measures, physical examination, and laboratory measurements is recommended in at-risk survivors. When endocrine disorders are suspected, healthcare providers should proceed with timely referrals to specialized services. These international evidence-based recommendations for surveillance of endocrine disorders in CAYA cancer survivors inform healthcare providers and highlight the need for long-term endocrine follow-up care in subgroups of survivors and elucidate opportunities for further research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2).
- Author
-
Stolze, Juliette, Teepen, Jop C., Raber-Durlacher, Judith E., Loonen, Jacqueline J., Kok, Judith L., Tissing, Wim J. E., de Vries, Andrica C. H., Neggers, Sebastian J. C. M. M., van Dulmen-den Broeder, Eline, van den Heuvel-Eibrink, Marry M., van der Pal, Helena J. H., Versluys, A. Birgitta, van der Heiden-van der Loo, Margriet, Louwerens, Marloes, Kremer, Leontien C. M., Brand, Henk S., and Bresters, Dorine
- Subjects
RESEARCH ,CROSS-sectional method ,SALIVA ,ORAL health ,TUMORS in children ,TREATMENT effectiveness ,RISK assessment ,CANCER patients ,XEROSTOMIA ,SURVIVAL analysis (Biometry) ,HEALTH care teams ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,SALIVARY gland diseases ,POISSON distribution ,DISEASE risk factors ,CHILDREN - Abstract
Simple Summary: Salivary gland dysfunction is an underestimated late effect in childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch Childhood Cancer Survivor Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS with a long-term follow-up exceeding 15 years. From February 2016 until March 2020, 292 CCS were included. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia did not correlate significantly. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary glands. Screening for hyposalivation during long-term follow-up in CCS is recommended in order to provide optimal oral supportive care aimed to improve oral health. Background: Limited data are available on the risk factors of salivary gland dysfunction in long-term childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch CCS Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS. Methods: From February 2016 until March 2020, 292 CCS were included. Data with regard to gender, age at study, diagnosis, age at diagnosis, and treatment characteristics were collected, as well as the unstimulated (UWS) and stimulated whole salivary flow rate (SWS). Xerostomia was assessed with the Xerostomia Inventory (XI) questionnaire. Multivariable Poisson regression analyses were used to evaluate the association between potential risk factors and the occurrence of hyposalivation. Results: The minimum time between diagnosis and study enrollment was 15 years. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia were not significantly correlated. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary gland region. Conclusion: Considering the importance of saliva for oral health, screening for hyposalivation in CCS is suggested in order to provide optimal oral supportive care aimed to improve oral health. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. The Impact of Cancer-Related Fatigue on HRQOL in Survivors of Childhood Cancer: A DCCSS LATER Study.
- Author
-
Penson, Adriaan, Walraven, Iris, Bronkhorst, Ewald, Maurice-Stam, Heleen, Grootenhuis, Martha A., Van der Heiden-van der Loo, Margriet, Tissing, Wim J. E., Van der Pal, Helena J. H., De Vries, Andrica C. H., Bresters, Dorine, Ronckers, Cécile, Van den Heuvel, Marry M., Neggers, Sebastian J. C. M. M., Versluys, Birgitta A. B., Louwerens, Marloes, Pluijm, Saskia M. F., Kremer, Leontien C. M., Blijlevens, Nicole, Van Dulmen-den Broeder, Eline, and Knoop, Hans
- Subjects
CANCER patient psychology ,CONFIDENCE intervals ,CANCER ,T-test (Statistics) ,CANCER fatigue ,QUALITY of life ,ANALYSIS of covariance ,LOGISTIC regression analysis ,ODDS ratio ,LONGITUDINAL method ,CHILDREN - Abstract
Simple Summary: Survivors of childhood cancer have an increased risk to experience symptoms of severe and persistent fatigue. We studied how fatigue might affect the health-related quality of life of these survivors. Questionnaire items asking about a broad range of daily life aspects were compared between fatigued survivors, survivors without fatigue and the general Dutch population. A total of eleven aspects were studied which were all negatively affected by fatigue, with the largest impact seen for Vitality (how much energy does a person have), General Health (perception of current and future health) and Role Limitations (work-related activities). Results show the negative impact fatigue can have on the daily lives of survivors and why it is important to treat fatigue adequately. Background: Early detection and management of late effects of treatment and their impact on health-related quality of life (HRQOL) has become a key goal of childhood cancer survivorship care. One of the most prevalent late effects is chronic fatigue (CF). The current study aimed to investigate the association between CF and HRQOL in a nationwide cohort of CCS. Methods: Participants were included from the Dutch Childhood Cancer Survivor Study (DCCSS) LATER cohort, a nationwide cohort of CCS. Participants completed the Checklist Individual Strength (CIS) to indicate CF (CIS fatigue severity subscale ≥ 35 and duration of symptoms ≥6 months) and the Short Form-36 (SF-36) and TNO (Netherlands Organization for Applied Scientific Research) and AZL (Leiden University Medical Centre) Adult's Health-Related Quality of Life questionnaire (TAAQOL) as measures for HRQOL. Differences in mean HRQOL domain scores between CF and non-CF participants were investigated using independent samples t-tests and ANCOVA to adjust for age and sex. The association between CF and impaired HRQOL (scoring ≥ 2 SD below the population norm) was investigated using logistic regression analyses, adjusting for confounders. Results: A total of 1695 participants were included in the study. Mean HRQOL domain scores were significantly lower in participants with CF. In addition, CF was associated with impaired HRQOL on all of the domains (except physical functioning) with adjusted odds ratios ranging from 2.1 (95% CI 1.3–3.4; sexuality domain) to 30.4 (95% CI 16.4–56.2; vitality domain). Conclusions: CF is associated with impaired HRQOL, urging for the screening and regular monitoring of fatigue, and developing possible preventative programs and interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Approach to the Patient With Treatment-resistant Acromegaly.
- Author
-
Coopmans, Eva C., van der Lely, Aart J., and Neggers, Sebastian J. C. M. M.
- Subjects
ACROMEGALY ,SOMATOSTATIN receptors ,RADIOTHERAPY - Abstract
Although most tumors in patients with acromegaly are benign and are cured or controlled by surgery and/or first-generation somatostatin receptor ligands therapy, some can behave more aggressively and are resistant to these standard therapies. Acromegaly, if left untreated, is a rare and chronic disorder, commonly caused by a GH-producing pituitary adenoma and is associated with significant comorbidities and an increased mortality. Transsphenoidal surgery is considered the mainstay of acromegaly management, but medical therapy has an increasingly important role. However, disease activity is not fully controlled in a significant number of patients treated with surgery and/or high-dose first-generation somatostatin receptor ligand monotherapy. In these circumstances, therefore, repeated surgery, second-line medical therapy, and radiotherapy, alone or combined as multimodal therapeutic strategies should be considered, in a patient-centered perspective. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study.
- Author
-
van Santen, Selveta S., Wolf, Peter, Kremenevski, Natalia, Boguszewski, Cesar L., Beiglböck, Hannes, Fiocco, Marta, Wijnen, Mark, Wallenius, Ville R., van den Heuvel-Eibrink, Marry M., van der Lely, Aart J., Johannsson, Gudmundur, Luger, Anton, Krebs, Michael, Buchfelder, Michael, Delhanty, Patric J. D., Neggers, Sebastian J. C. M. M., and Olsson, Daniel S.
- Subjects
BARIATRIC surgery ,HYPOTHALAMIC hormones ,CRANIOPHARYNGIOMA ,OBESITY ,RETROSPECTIVE studies ,PROGNOSIS ,CASE-control method ,GASTRIC bypass ,BODY mass index ,LONGITUDINAL method ,DISEASE complications - Abstract
Context: Craniopharyngioma is a sellar tumor associated with high rates of pituitary deficiencies (~ 98%) and hypothalamic obesity (~ 50%).Objective: This work aims to determine the efficacy regarding long-term weight loss after bariatric surgery in obese craniopharyngioma patients with hypothalamic dysfunction.Methods: This retrospective, case-control, multicenter, international study included obese craniopharyngioma patients (N = 16; of whom 12 are women) with a history of bariatric surgery (12 Roux-en-Y gastric bypass, 4 sleeve gastrectomy; median age 21 years [range, 15-52 years], median follow-up 5.2 years [range, 2.0-11.3 years]) and age/sex/surgery/body mass index-matched obese controls (N = 155). Weight loss and obesity-related comorbidities up to 5 years after bariatric surgery were compared and changes in hormonal replacement therapy evaluated.Results: Mean weight loss at 5-year follow-up was 22.0% (95% CI, 16.1%-27.8%) in patients vs 29.5% (95% CI, 28.0%-30.9%) in controls (P = .02), which was less after Roux-en-Y gastric bypass (22.7% [16.9%-28.5%] vs 32.0% [30.4%-33.6%]; P = .003) but at a similar level after sleeve gastrectomy (21.7% [-1.8% to 45.2%] vs 21.8% [18.2%-25.5%]; P = .96). No major changes in endocrine replacement therapy were observed after surgery. One patient died (unknown cause). One patient had long-term absorptive problems.Conclusion: Obese patients with craniopharyngioma had a substantial mean weight loss of 22% at 5-year follow-up after bariatric surgery, independent of type of bariatric surgery procedure. Weight loss was lower than in obese controls after Roux-en-Y gastric bypass. Bariatric surgery appears to be effective and relatively safe in the treatment of obese craniopharyngioma patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review.
- Author
-
Pluimakers, Vincent G., van Santen, Selveta S., Fiocco, Marta, Bakker, Marie‐Christine E., van der Lelij, Aart J., van den Heuvel‐Eibrink, Marry M., and Neggers, Sebastian J. C. M. M.
- Subjects
CHILDHOOD cancer ,METABOLIC syndrome ,CANCER survivors ,DIAGNOSIS ,CARDIOVASCULAR diseases - Abstract
Summary: Childhood cancer survivors (CCS) are at increased risk to develop metabolic syndrome (MetS), diabetes, and cardiovascular disease. Common criteria underestimate adiposity and possibly underdiagnose MetS, particularly after abdominal radiotherapy. A systematic literature review and meta‐analysis on the diagnostic and predictive value of nine newer MetS related biomarkers (adiponectin, leptin, uric acid, hsCRP, TNF‐alpha, IL‐1, IL‐6, apolipoprotein B (apoB), and lipoprotein(a) [lp(a)]) in survivors and adult non‐cancer survivors was performed by searching PubMed and Embase. Evidence was summarized with GRADE after risk of bias evaluation (QUADAS‐2/QUIPS). Eligible studies on promising biomarkers were pooled. We identified 175 general population and five CCS studies. In the general population, valuable predictive biomarkers are uric acid, adiponectin, hsCRP and apoB (high level of evidence), and leptin (moderate level of evidence). Valuable diagnostic biomarkers are hsCRP, adiponectin, uric acid, and leptin (low, low, moderate, and high level of evidence, respectively). Meta‐analysis showed OR for hyperuricemia of 2.94 (age‐/sex‐adjusted), OR per unit uric acid increase of 1.086 (unadjusted), and AUC for hsCRP of 0.71 (unadjusted). Uric acid, adiponectin, hsCRP, leptin, and apoB can be alternative biomarkers in the screening setting for MetS in survivors, to enhance early identification of those at high risk of subsequent complications. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study.
- Author
-
Coopmans, Eva C., Postma, Mark R., Wolters, Thalijn L. C., van Meyel, Sebastiaan W. F., Netea-Maier, Romana, van Beek, André P., and Neggers, Sebastian J. C. M. M.
- Subjects
ACROMEGALY ,FORECASTING ,SURGERY - Abstract
Context: Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. It is important to identify patients in whom surgical cure is not attainable at an early stage, both to inform patients on expected treatment outcome and to select those who are more likely to need additional therapy.Objective: To identify predictors for remission after TSS in acromegaly.Methods: Large multicenter study with retrospective data collection from 3 tertiary neurosurgical referral centers in The Netherlands. We analyzed clinical data since 2000 from 3 cohorts (Groningen, Nijmegen, and Rotterdam, total n = 282). Multivariate regression models were used to identify predictors of early biochemical remission (12 weeks to 1 year postoperatively) according to the 2010 consensus criteria, long-term remission (age- and sex-normalized insulin-like growth factor 1 [IGF-1] and the absence of postoperative treatment until last follow-up), and relative IGF-1 and growth hormone [GH] reduction.Results: A larger maximum tumor diameter (odds ratio [OR] 0.91, 95% CI 0.87-0.96, P ≤ .0001) was associated with a lower chance of early biochemical remission. A larger maximum tumor diameter (OR 0.93, 95% CI 0.89-0.97, P = .0022) and a higher random GH concentration at diagnosis (OR 0.98, 95% CI 0.96-0.99, P = .0053) were associated with a lower chance of long-term remission.Conclusion: Maximum tumor diameter and random GH concentration at diagnosis are the best predictors for remission after TSS in acromegaly. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
22. Congenital hypopituitarism in two brothers with a duplication of the 'acrogigantism gene' GPR101: clinical findings and review of the literature.
- Author
-
Elizabeth, Melitza S. M., Verkerk, Annemieke J. M. H., Hokken-Koelega, Anita C. S., Verlouw, Joost A. M., Argente, Jesús, Pfaeffle, Roland, Neggers, Sebastian J. C. M. M., Visser, Jenny A., and de Graaff, Laura C. G.
- Abstract
Purpose: Congenital hypopituitarism (CH) can cause significant morbidity or even mortality. In the majority of patients, the etiology of CH is unknown. Understanding the etiology of CH is important for anticipation of clinical problems and for genetic counselling. Our previous studies showed that only a small proportion of cases have mutations in the known 'CH genes'. In the current project, we present the results of SNP array based copy number variant analysis in a family with unexplained congenital hypopituitarism. Methods: DNA samples of two affected brothers with idiopathic CH and their mother were simultaneously analyzed by SNP arrays for copy number variant analysis and Whole Exome Sequencing (WES) for mutation screening. DNA of the father was not available. Results: We found a 6 Mb duplication including GPR101 and SOX3 on the X-chromosome (Xq26.2-q27.1) in the two siblings and their mother, leading to 2 copies of this region in the affected boys and 3 copies in the mother. Duplications of GPR101 are associated with X-linked acrogigantism (the phenotypic 'opposite' of the affected brothers), whereas alterations in SOX3 are associated with X-linked hypopituitarism. Conclusion: In our patients with hypopituitarism we found a 6 Mb duplication which includes GPR101, a gene associated with X- linked gigantism, and SOX3, a gene involved in early pituitary organogenesis that is associated with variable degrees of hypopituitarism. Our findings show that in duplications containing both GPR101 and SOX3, the growth hormone deficiency phenotype is dominant. This suggests that, if GPR101 is duplicated, it might not be expressed phenotypically when early patterning of the embryonic pituitary is affected due to SOX3 duplication. These results, together with the review of the literature, shed a new light on the role of GPR101 and SOX3 in pituitary function. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years.
- Author
-
Santen, Selveta S. van, Olsson, Daniel S., Hammarstrand, Casper, Wijnen, Mark, Fiocco, Marta, van den Heuvel-Eibrink, Marry M., Johannsson, Gudmundur, Janssen, Joseph A. M. J. L., der Lely, Aart J. van, Neggers, Sebastian J. C. M. M., van Santen, Selveta S, and van der Lely, Aart J
- Subjects
BONE density ,BONES ,BODY composition ,CRANIOPHARYNGIOMA ,HYPOTHALAMUS ,LONGITUDINAL method ,LEAN body mass ,VAGUS nerve ,PHOTON absorptiometry ,TIME ,RETROSPECTIVE studies ,PITUITARY tumors ,BODY mass index - Abstract
Context: Patients with craniopharyngioma suffer from obesity and impaired bone health. Little is known about longitudinal changes in body composition and bone mineral density (BMD).Objective: To describe body composition and BMD (change).Design: Retrospective longitudinal study.Setting: Two Dutch/Swedish referral centers.Patients: Patients with craniopharyngioma (n = 112) with a dual X-ray absorptiometry (DXA) scan available (2 DXA scans, n = 86; median Δtime 10.0 years; range 0.4-23.3) at age ≥ 18 years (58 [52%] male, 50 [45%] childhood onset).Main Outcome Measures: Longitudinal changes of body composition and BMD, and associated factors of ΔZ-score (sex and age standardized).Results: BMI (from 28.8 ± 4.9 to 31.2 ± 5.1 kg/m2, P < .001), fat mass index (FMI) (from 10.5 ± 3.6 to 11.9 ± 3.8 kg/m2, P = .001), and fat free mass index (FFMI) (from 18.3 ± 3.2 to 19.1 ± 3.2 kg/m2, P < .001) were high at baseline and increased. Fat percentage and Z-scores of body composition did not increase, except for FFMI Z-scores (from 0.26 ± 1.62 to 1.06 ± 2.22, P < .001). Z-scores of total body, L2-L4, femur neck increased (mean difference 0.61 ± 1.12, P < .001; 0.74 ± 1.73, P < .001; 0.51 ± 1.85, P = .02). Linear regression models for ΔZ-score were positively associated with growth hormone replacement therapy (GHRT) (femur neck: beta 1.45 [95% CI 0.51-2.39]); and negatively with radiotherapy (femur neck: beta -0.79 [-1.49 to -0.09]), glucocorticoid dose (total body: beta -0.06 [-0.09 to -0.02]), and medication to improve BMD (L2-L4: beta -1.06 [-1.84 to -0.28]).Conclusions: Z-scores of BMI, fat percentage, and FMI remained stable in patients with craniopharyngioma over time, while Z-scores of FFMI and BMD increased. Higher glucocorticoid dose and radiotherapy were associated with BMD loss and GHRT with increase. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
24. Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes.
- Author
-
Vila, Greisa, Luger, Anton, van der Lely, Aart Jan, Neggers, Sebastian J. C. M. M., Webb, Susan M., Biller, Beverly M. K., Valluri, Srinivas, and Hey-Hadavi, Judith
- Subjects
ACROMEGALY ,CARDIOVASCULAR diseases risk factors ,DEATH rate ,HEALTH outcome assessment ,HYPERTENSION ,BLOOD pressure - Abstract
Context: Hypertension is a major cardiovascular risk factor related to increased mortality in acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure levels, however little is known about the effect of pegvisomant (PEGV) treatment in patients with hypertension. This analysis evaluates outcomes in patients with hypertension and acromegaly included in ACROSTUDY. Methods: ACROSTUDY is a global non-interventional surveillance study of long-term treatment with PEGV, monitoring its safety and efficacy. The cohort was retrospectively divided in two subgroups: patients with and without hypertension. Stepwise logistic regression and Kaplan-Meyer analyses were performed for testing predictors of mortality. Results: The total cohort included 2,090 patients with acromegaly treated with PEGV who were followed for a median of 6.8 years (range up to 12.1 years). In ACROSTUDY there were 1,344 patients with hypertension (52.3% males). This subgroup was older, had a higher BMI, and higher prevalence of diabetes, hyperlipidemia, and cardiovascular disease (CVD) when compared to patients without hypertension. During ACROSTUDY, 68 deaths were reported in the hypertension cohort, vs 10 in the cohort without hypertension. Both CVD (p<0.0001) and anterior pituitary deficiencies (p=0.0105) at study entry independently predicted mortality in patients with acromegaly and hypertension; Kaplan-Meier analysis confirmed that CVD significantly impairs survival. Conclusions: Hypertension is common in patients with acromegaly and significantly increases mortality, especially when there is concomitant CVD. These data suggest that treatment goals should extend beyond IGF-I normalization, and include optimisation of substitution of pituitary deficiencies and scrutinous screening and treatment of CVD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
- Author
-
Coopmans, Eva C., Korevaar, Tim I. M., van Meyel, Sebastiaan W. F., Daly, Adrian F., Chanson, Philippe, Brue, Thierry, Delemer, Brigitte, Hána Jr., Václav, Colao, Annamaria, Carvalho, Davide, Jaffrain-Rea, Marie-Lise, Stalla, Günter K., Fajardo-Montañana, Carmen, Beckers, Albert, der Lely, Aart J. van, Petrossians, Patrick, Neggers, Sebastian J. C. M. M., Hána, Václav, and van der Lely, Aart J
- Subjects
SOMATOSTATIN receptors ,ACROMEGALY ,BIOCHEMICAL models ,PITUITARY dwarfism ,PREDICTION models ,SOMATOMEDIN C ,DOPAMINE receptors ,ADENOMATOUS polyps ,BIOMARKERS ,SOMATOMEDIN ,RESEARCH ,MATHEMATICAL models ,MULTIVARIATE analysis ,RESEARCH methodology ,CELL receptors ,OCTREOTIDE acetate ,PROGNOSIS ,RETROSPECTIVE studies ,EVALUATION research ,MEDICAL cooperation ,TREATMENT effectiveness ,HUMAN growth hormone ,COMPARATIVE studies ,SOMATOSTATIN ,THEORY ,LONGITUDINAL method ,LIGANDS (Biochemistry) ,PEPTIDES - Abstract
Context: First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs.Objective: To identify clinical predictors of the biochemical response to fg-SRLs monotherapy defined as biochemical response (insulin-like growth factor (IGF)-1 ≤ 1.3 × ULN (upper limit of normal)), partial response (>20% relative IGF-1 reduction without normalization), and nonresponse (≤20% relative IGF-1 reduction), and IGF-1 reduction.Design: Retrospective multicenter study.Setting: Eight participating European centers.Methods: We performed a meta-analysis of participant data from 2 cohorts (Rotterdam and Liège acromegaly survey, 622 out of 3520 patients). Multivariable regression models were used to identify predictors of biochemical response to fg-SRL monotherapy.Results: Lower IGF-1 concentration at baseline (odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.72-0.95 IGF-1 ULN, P = .0073) and lower bodyweight (OR = 0.99, 95% CI 0.98-0.99 kg, P = .038) were associated with biochemical response. Higher IGF-1 concentration at baseline (OR = 1.40, (1.19-1.65) IGF-1 ULN, P ≤ .0001), the presence of type 2 diabetes (oral medication OR = 2.48, (1.43-4.29), P = .0013; insulin therapy OR = 2.65, (1.02-6.70), P = .045), and higher bodyweight (OR = 1.02, (1.01-1.04) kg, P = .0023) were associated with achieving partial response. Younger patients at diagnosis are more likely to achieve nonresponse (OR = 0.96, (0.94-0.99) year, P = .0070). Baseline IGF-1 and growth hormone concentration at diagnosis were associated with absolute IGF-1 reduction (β = 0.90, standard error (SE) = 0.02, P ≤ .0001 and β = 0.002, SE = 0.001, P = .014, respectively).Conclusion: Baseline IGF-1 concentration was the best predictor of biochemical response to fg-SRL, followed by bodyweight, while younger patients were more likely to achieve nonresponse. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. Soluble Klotho: a possible predictor of quality of life in acromegaly patients.
- Author
-
Coopmans, Eva C., El-Sayed, Nour, Frystyk, Jan, Magnusson, Nils E., Jørgensen, Jens O. L., van der Lely, Aart-Jan, Janssen, Joop A. M. J. L., Muhammad, Ammar, and Neggers, Sebastian J. C. M. M.
- Abstract
Purpose: Although quality of life (QoL) is improved in patients with acromegaly after disease control, QoL correlates only weakly with traditional biomarkers. Our objective is to investigate a potential relation between the new serum biomarker soluble Klotho (sKlotho), GH and insulin-like growth factor 1 (IGF-1) levels, and QoL. Methods: In this prospective cohort study, we investigated 54 acromegaly patients biochemically well-controlled on combination treatment with first-generation somatostatin receptor ligands (SRLs) and pegvisomant (PEGV) at baseline and 9 months after switching to pasireotide LAR (PAS-LAR; either as monotherapy, n = 28; or in combination with PEGV, n = 26). QoL was measured by the Patient-Assessed Acromegaly Symptom Questionnaire (PASQ) and Acromegaly Quality of Life (AcroQoL) questionnaire. Results: Switching to PAS-LAR treatment significantly improved QoL without altering IGF-1 levels. QoL did not correlate with GH or IGF-1 levels, but sKlotho correlated with the observed improvements in QoL by the AcroQoL global (r = −0.35, p = 0.012) and physical subdimension (r = −0.34, p = 0.017), and with PASQ headache (r = 0.28, p = 0.048), osteoarthralgia (r = 0.46, p = 0.00080) and soft tissue swelling score (r = 0.29, p = 0.041). Parallel changes in serum sKlotho and IGF-1 (r = 0.31, p = 0.023) suggest sKlotho and IGF-1 to be similarly dependent on GH. Comparing the PAS-LAR combination therapy and the monotherapy group we did not observe a significant difference in improvement of QoL. Conclusions: Patients experienced improved QoL during PAS-LAR, either as monotherapy or in combination with PEGV. Soluble Klotho concentrations appear to be a useful marker of QoL in acromegaly patients but the underlying mechanisms remain to be investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Increased number of retinal vessels in acromegaly.
- Author
-
Füchtbauer, Laila, Olsson, Daniel S., Coopmans, Eva C., Bengtsson, Bengt-Åke, Norrman, Lise-Lott, Neggers, Sebastian J. C. M. M., Hellström, Ann, and Johannsson, Gudmundur
- Subjects
RETINAL blood vessels ,SOMATOMEDIN C ,SOMATOTROPIN - Abstract
Objective: Excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), as in acromegaly, is associated with increased risk of diabetes, but whether retinal vessels are alt ered is unknown. The aim of this study was to evaluate retinal vessel morphology in patients with acromegaly at diagno sis and after treatment and to describe the prevalence of diabetic retinopathy in patients with long-standing acromega ly and diabetes. Design: Two independent observational studies, one being prospective a nd the other retrospective and cross-sectional. Methods: Retinal vessel morphology of 26 patients with acromegaly was e xamined at diagnosis and 1 year after treatment and compared to 13 healthy controls. Cross-sectional evaluation of 39 patients with long-standing acromegaly and diabetes was performed. Fundus photographs were digitally analyzed for vessel morphology. Results: Patients with acromegaly had a median (interquartile range) of 34.3 (30.0-39.0) vessel branching points compared to 27.0 (24.0-29.0) for healthy controls (P < 0.001). Tortuosity of arterioles and venules remained unchanged. Vessel morphology did not change significantly after treatment. Patients with acromegaly and diabetes for a median of 14 years also had a high number of branching po ints (34.2 (32.5-35.6)), but the prevalence of diabetic retinopathy was not higher than expected in diabetic patients w ithout acromegaly. Conclusions: Patients with acromegaly have an increased number of vascular branching points in the retina without an alteration of macroscopic vessel morphology. This is consistent with an angiogenic effect of GH/IGF-1 in humans. The prevalence of diabetic retinopathy was not increased in patient s with acromegaly and diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Endocrine Disorders Are Prominent Clinical Features in Patients With Primary Antibody Deficiencies.
- Author
-
Coopmans, Eva C., Chunharojrith, Paweena, Neggers, Sebastian J. C. M. M., van der Ent, Marianne W., Swagemakers, Sigrid M. A., Hollink, Iris H., Barendregt, Barbara H., van der Spek, Peter J., van der Lely, Aart-Jan, van Hagen, P. Martin, and Dalm, Virgil A. S. H.
- Subjects
PITUITARY dwarfism ,PREMATURE ovarian failure ,CONGENITAL hypothyroidism ,IMMUNOGLOBULIN G ,AUTOIMMUNE thyroiditis ,ADRENAL insufficiency - Abstract
Background: Primary antibody deficiencies (PADs) and anterior pituitary dysfunction are both rare conditions. However, recent studies have remarkably reported the occurrence of anterior pituitary dysfunction in PAD patients. Methods: In this cross-sectional, single-center study we evaluated the prevalence of endocrine disorders in adult PAD patients. Our study focused on common variable immunodeficiency (CVID), immunoglobulin G (IgG) subclass deficiency (IgGSD), and specific anti-polysaccharide antibody deficiency (SPAD). We assessed hormone levels, performed provocative tests and genetic testing in a subset of patients by direct sequencing of the nuclear factor kappa beta subunit 2 (NFKB2) gene and primary immunodeficiency (PID) gene panel testing by whole exome sequencing (WES). Results: Our results demonstrated that one out of 24 IgGSD/SPAD patients had secondary hypothyroidism and three out of 9 men with IgGSD/SPAD had secondary hypogonadism. Premature ovarian failure was observed in four out of 9 women with CVID and primary testicular failure in one out of 15 men with CVID. In two out of 26 CVID patients we found partial adrenal insufficiency (AI) and in one out of 18 patients with IgGSD/SPAD secondary AI was found. Moreover, in one out of 23 patients with CVID and in two out of 17 patients with IgGSD/SPAD severe growth hormone deficiency (GHD) was found, while one patient with IgGSD/SPAD showed mild GHD. Combined endocrine disorders were detected in two women with CVID (either partial secondary AI or autoimmune thyroiditis with primary hypogonadism) and in three men with IgGSD/SPAD (two with either mild GHD or secondary hypothyroidism combined with secondary hypogonadism, and one man with secondary AI and severe GHD). Genetic testing in a subset of patients did not reveal pathogenic variants in NFKB2 or other known PID-associated genes. Conclusion: This is the first study to describe a high prevalence of both anterior pituitary and end-organ endocrine dysfunction in adult PAD patients. As these endocrine disorders may cause considerable health burden, assessment of endocrine axes should be considered in PAD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
- Author
-
Coopmans, Eva C., van Meyel, Sebastiaan W. F., Pieterman, Kay J., van Ipenburg, Jolique A., Hofland, Leo J., Donga, Esther, Daly, Adrian F., Beckers, Albert, der Lely, Aart-Jan van, and Neggers, Sebastian J. C. M. M.
- Subjects
PROLACTINOMA ,SOMATOSTATIN receptors ,DOPAMINE agonists ,ADENOMATOUS polyps ,SOMATOSTATIN ,TUMORS - Abstract
Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without temozolomide. Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy, a second-generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis or both was observed after PAS-LAR administration suggesting an antitumor effect. This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis or both in prolactinomas. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI.
- Author
-
van Santen, Selvetta S., Olsson, Daniel S., Hammarstrand, Casper, Wijnen, Mark, van den Heuvel-Eibrink, Marry M., van der Lely, Aart J., Johannsson, Gudmundur, Janssen, Joseph A. M. J. L., and Neggers, Sebastian J. C. M. M.
- Subjects
CRANIOPHARYNGIOMA ,METABOLIC syndrome ,BODY composition ,DUAL-energy X-ray absorptiometry ,METABOLIC profile tests - Abstract
Objective: Craniopharyngioma patients often have poor metabolic profiles due to hypothalamic–pituitary damage. Previously, using BMI as obesity marker, the occurrence of the metabolic syndrome in these patients was estimated at 46%. Our aim was to determine if dual X-ray absorptiometry (DXA) scan in evaluation of obesity and metabolic syndrome would be superior. Design: Retrospective study of craniopharyngioma patients for whom DXA scan results were available. Methods: BMI, fat percentage and fat mass index were used to evaluate obesity and as components for obesity in metabolic syndrome. Results: Ninety-five craniopharyngioma patients were included (51% female, 49% childhood-onset disease). Metabolic syndrome occurred in 34–53 (45–51%) subjects (depending on the definition of obesity, although all definitions occurred in higher frequency than in the general population). Metabolic syndrome frequency was higher if obesity was defined by fat percentage (52 vs 42%) or fat mass index (51 vs 43%) compared to BMI. Misclassification appeared in 9% (fat percentage vs BMI) and 7% (fat mass index vs BMI) for metabolic syndrome and 29 and 13% for obesity itself, respectively. For metabolic syndrome, almost perfect agreement was found for BMI compared with fat percentage or fat mass index. For obesity, agreement was fair to moderate (BMI vs fat percentage). Conclusion: Using BMI to evaluate obesity underestimates the true prevalence of metabolic syndrome in patients with craniopharyngioma. Furthermore, fat percentage contributes to a better evaluation of obesity than BMI. The contribution of DXA scan might be limited for identification of the metabolic syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer.
- Author
-
Kok, Judith L., Teepen, Jop C., van der Pal, Helena J., van Leeuwen, Flora E., Tissing, Wim J. E., Neggers, Sebastian J. C. M. M., Loonen, Jacqueline J., Louwerens, Marloes, Versluys, Birgitta, van den Heuvel-Eibrink, Marry M., van Dulmen-den Broeder, Eline, Jaspers, Monique M. W., van Santen, Hanneke M., van der Heiden-van der Loo, Margriet, Janssens, Geert O., Maduro, John H., Bruggink, Annette H., Jongmans, Marjolijn C., Kremer, Leontien C. M., and Ronckers, Cécile M.
- Published
- 2019
- Full Text
- View/download PDF
32. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age.
- Author
-
Kok, Judith L, Teepen, Jop C, Leeuwen, Flora E van, Tissing, Wim J E, Neggers, Sebastian J C M M, Pal, Helena J van der, Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, Heuvel-Eibrink, Marry M van den, Broeder, Eline van Dulmen-den, Loo, Margriet van der Heiden-van der, Aleman, Berthe M P, Daniels, Laurien A, Haasbeek, Cornelis J A, Hoeben, Bianca, Janssens, Geert O, Maduro, John H, Oldenburger, Foppe, and Rij, Caroline van
- Published
- 2019
- Full Text
- View/download PDF
33. Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study.
- Author
-
(Lieke) Feijen, E. A. M., Font-Gonzalez, Anna, Van der Pal, Helena J. H., Kok, Wouter E. M., Geskus, Ronald B., Ronckers, Cécile M., Bresters, Dorine, van Dalen, Elvira C., van Dulmen-den Broeder, Eline, van den Berg, Marleen H., van der Heiden-van der Loo, Margriet, van den Heuvel-Eibrink, Marry M., van Leeuwen, Flora E., Loonen, Jacqueline J., Neggers, Sebastian J. C. M. M., Versluys, A. B. (Birgitta), Tissing, Wim J. E., Kremer, Leontien C. M., Feijen, E A M Lieke, and DCOG‐LATER Study Group
- Published
- 2019
- Full Text
- View/download PDF
34. Fatigue After Aneurysmal Subarachnoid Hemorrhage Is Highly Prevalent in the First-Year Postonset and Related to Low Physical Fitness: A Longitudinal Study.
- Author
-
Harmsen, Wouter J., Ribbers, Gerard M., Heijenbrok-Kal, Majanka H., Khajeh, Ladbon, Sneekes, Emiel M., van Kooten, Fop, Neggers, Sebastian J. C. M. M., and van den Berg-Emons, Rita J.
- Published
- 2019
- Full Text
- View/download PDF
35. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study.
- Author
-
Muhammad, Ammar, Coopmans, Eva C., Delhanty, Patric J. D., Dallenga, Alof H. G., Haitsma, Iain K., Janssen, Joseph A. M. J. L., van der Lely, Aart J., and Neggers, Sebastian J. C. M. M.
- Subjects
ACROMEGALY ,SOMATOSTATIN ,DRUG efficacy - Abstract
Objective: To assess the efficacy and safety after 48 weeks of treatment with pasireotide long-acting-release (PAS-LAR) alone or in combination with pegvisomant in patients with acromegaly. In addition, we assessed the relation between insulin secretion and pasireotide-induced hyperglycemia. Design: The PAPE extension study is a prospective follow-up study until 48 weeks after the core study of 24 weeks. Methods: Fifty-nine out of 61 patients entered the extension study. Efficacy was defined as the percentage of patients achieving IGF-I normalization (=1.2× the upper limit of normal (ULN)) at 48 weeks through protocol-based adjustment of pegvisomant and PAS-LAR doses. At baseline, insulin secretion was assessed by an oral glucose tolerance test (OGTT). Results: At the end of the study, median IGF-I was 0.98× ULN, and 77% of patients achieved normal IGF-I levels with a mean pegvisomant dose of 64 mg/week, and an overall cumulative pegvisomant dose reduction of 52%. Frequency of diabetes mellitus increased from 68% at 24 weeks to 77% at 48 weeks, and nine patients discontinued PAS-LAR treatment, mainly because of severe hyperglycemia. Pasireotide-induced hyperglycemia was inversely correlated with baseline insulin secretion (r = -0.37, P < 0.005). Conclusions: PAS-LAR normalizes IGF-I levels in most acromegaly patients, with a 50% pegvisomant-sparing effect. However, PAS-LAR treatment coincided with a high incidence of diabetes mellitus. The risk for developing diabetes during PAS-LAR treatment seems inversely related to insulin secretion at baseline. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions.
- Author
-
Daly, Adrian F., Castermans, Emilie, Oudijk, Lindsey, Guitelman, Mirtha A., Beckers, Pablo, Potorac, Iulia, Neggers, Sebastian J. C. M. M., Sacre, Nathalie, van der Lely, Aart-Jan, Bours, Vincent, de Herder, Wouter W., and Beckers, Albert
- Subjects
PHEOCHROMOCYTOMA ,ADRENAL tumors ,EXONS (Genetics) ,ENDOCRINE gland tumors ,ADENOMA ,PATHOLOGICAL physiology - Published
- 2018
- Full Text
- View/download PDF
37. Health-related fitness in very long-term survivors of childhood cancer: A cross-sectional study.
- Author
-
Hartman, Annelies, Pluijm, Saskia M. F., Wijnen, Mark, Neggers, Sebastian J. C. M. M., Clemens, Eva, Pieters, Rob, van den Heuvel‐Eibrink, Marry M., and van den Heuvel-Eibrink, Marry M
- Published
- 2018
- Full Text
- View/download PDF
38. Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study.
- Author
-
Wijnen, Mark, Olsson, Daniel S., van den Heuvel-Eibrink, Marry M., Hammarstrand, Casper, Janssen, Joseph A. M. J. L., van der Lely, Aart J., Johannsson, Gudmundur, and Neggers, Sebastian J. C. M. M.
- Subjects
CRANIOPHARYNGIOMA ,CANCER-related mortality ,MYOCARDIAL infarction - Abstract
Objective: Most studies in patients with craniopharyngioma did not investigate morbidity and mortality relative to the general population nor evaluated risk factors for excess morbidity and mortality. Therefore, the objective of this study was to examine excess morbidity and mortality, as well as their determinants in patients with craniopharyngioma. Design: Hospital-based retrospective cohort study conducted between 1987 and 2014. Methods: We included 144 Dutch and 80 Swedish patients with craniopharyngioma identified by a computer-based search in the medical records (105 females (47%), 112 patients with childhood-onset craniopharyngioma (50%), 3153 personyears of follow-up). Excess morbidity and mortality were analysed using standardized incidence and mortality ratios (SIRs and SMRs). Risk factors were evaluated univariably by comparing SIRs and SMRs between non-overlapping subgroups. Results: Patients with craniopharyngioma experienced excess morbidity due to type 2 diabetes mellitus (T2DM) (SIR: 4.4, 95% confidence interval (CI): 2.8-6.8) and cerebral infarction (SIR: 4.9, 95% CI: 3.1-8.0) compared to the general population. Risks for malignant neoplasms, myocardial infarctions and fractures were not increased. Patients with craniopharyngioma also had excessive total mortality (SMR: 2.7, 95% CI: 2.0-3.8), and mortality due to circulatory (SMR: 2.3, 95% CI: 1.1-4.5) and respiratory (SMR: 6.0, 95% CI: 2.5-14.5) diseases. Female sex, childhood-onset craniopharyngioma, hydrocephalus and tumour recurrence were identified as risk factors for excess T2DM, cerebral infarction and total mortality. Conclusions: Patients with craniopharyngioma are at an increased risk for T2DM, cerebral infarction, total mortality and mortality due to circulatory and respiratory diseases. Female sex, childhood-onset craniopharyngioma, hydrocephalus and tumour recurrence are important risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
39. The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up.
- Author
-
Wijnen, Mark, Olsson, Daniel S., van den Heuvel-Eibrink, Marry M., Hammarstrand, Casper, Janssen, Joseph A. M. J. L., van der Lely, Aart-Jan, Johannsson, Gudmundur, and Neggers, Sebastian J. C. M. M.
- Subjects
METABOLIC syndrome ,CRANIOPHARYNGIOMA ,CARDIOVASCULAR disease related mortality ,THERAPEUTICS - Abstract
Objective: Patients with craniopharyngioma are at an increased risk for cardio- and cerebrovascular mortality. The metabolic syndrome (MetS) is an important cardiometabolic risk factor, but barely studied in patients with craniopharyngioma. We aimed to investigate the prevalence of and risk factors for the MetS and its components in patients with craniopharyngioma. Design: Cross-sectional study with retrospective data. Methods: We studied the prevalence of and risk factors for the MetS and its components in 110 Dutch (median age 47 years, range 18-92) and 68 Swedish (median age 50 years, range 20-81) patients with craniopharyngioma with ≤3 years of follow-up (90 females (51%); 83 patients with childhood-onset craniopharyngioma (47%); median follow-up after craniopharyngioma diagnosis 16 years (range 3-62)). In Dutch patients aged 30-70 years and Swedish patients aged 45-69 years, we examined the prevalence of the MetS and its components relative to the general population. Results: Sixty-nine (46%) of 149 patients with complete data demonstrated the MetS. Prevalence of the MetS was significantly higher in patients with craniopharyngioma compared with the general population (40% vs 26% (P < 0.05) for Dutch patients; 52% vs 15% (P < 0.05) for Swedish patients). Multivariable logistic regression analysis identified visual impairment as a borderline significant predictor of the MetS (OR 2.54, 95% CI 0.95-6.81; P = 0.06) after adjustment for glucocorticoid replacement therapy and follow-up duration. Age, female sex, tumor location, radiological hypothalamic damage,
90 Yttrium brachytherapy, glucocorticoid replacement therapy and follow-up duration significantly predicted components of the MetS. Conclusions: Patients with craniopharyngioma are at an increased risk for the MetS, especially patients with visual impairment. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
40. Inactive lifestyles and sedentary behavior in persons with chronic aneurysmal subarachnoid hemorrhage: evidence from accelerometer-based activity monitoring.
- Author
-
Harmsen, Wouter J., Ribbers, Gerard M., Heijenbrok-Kal, Majanka H., Bussmann, Johannes B. J., Sneekes, Emiel M., Khajeh, Ladbon, van Kooten, Fop, Neggers, Sebastian J. C. M. M., and van den Berg-Emons, Rita J.
- Subjects
SEDENTARY lifestyles ,UNHEALTHY lifestyles ,SUBARACHNOID hemorrhage ,ACCELEROMETERS ,PHYSICAL activity ,STROKE risk factors ,PATIENTS ,EXERCISE ,PATIENT monitoring ,RESEARCH funding ,ACCELEROMETRY ,DISEASE complications - Abstract
Background: Aneurysmal subarachnoid hemorrhage (a-SAH) is a potential life-threatening stroke. Because survivors may be at increased risk for inactive and sedentary lifestyles, this study evaluates physical activity (PA) and sedentary behavior (SB) in the chronic phase after a-SAH.Methods: PA and SB were objectively measured at six months post a-SAH with an accelerometer-based activity monitor, with the aim to cover three consecutive weekdays. Total time spent in PA (comprising walking, cycling, running and non-cyclic movement) and SB (comprising sitting and lying) was determined. Also, in-depth analyses were performed to determine the accumulation and distribution of PA and SB throughout the day. Binary time series were created to determine the mean bout length and the fragmentation index. Measures of PA and SB in persons with a-SAH were compared to those in sex- and age-matched healthy controls.Results: The 51 participants comprised 33 persons with a-SAH and 18 controls. None of the participants had signs of paresis or spasticity. Persons with a-SAH spent 105 min/24 h being physically active, which was 35 min/24 h less than healthy controls (p = 0.005). For PA, compared with healthy controls, the mean bout length was shorter in those with a-SAH (12.0 vs. 13.5 s, p = 0.006) and the fragmentation index was higher (0.053 vs. 0.041, p < 0.001). Total sedentary time during waking hours showed no significant difference between groups (514 min vs. 474 min, p = 0.291). For SB, the mean bout length was longer in persons with a-SAH (122.3 vs. 80.5 s, p = 0.024), whereas there was no difference in fragmentation index between groups (0.0032 vs 0.0036, p = 0.396).Conclusions: Persons with a-SAH are less physically active, they break PA time into shorter periods, and SB periods last longer compared to healthy controls. Since inactive lifestyles and prolonged uninterrupted periods of SB are independent risk factors for poor cardiovascular health, interventions seem necessary and should target both PA and SB.Study Registration: Dutch registry number: NTR 2085. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
41. Very long-term sequelae of craniopharyngioma.
- Author
-
Wijnen, Mark, van den Heuvel-Eibrink, Marry M., Janssen, Joseph A. M. J. L., Catsman-Berrevoets, Coriene E., Michiels, Erna M. C., van Veelen-Vincent, Marie-Lise C., Dallenga, Alof H. G., van den Berge, J. Herbert, van Rij, Carolien M., van der Lely, Aart-Jan, and Neggers, Sebastian J. C. M. M.
- Subjects
CRANIOPHARYNGIOMA ,BRAIN tumor diagnosis ,CYSTS (Pathology) ,RADIOTHERAPY ,PITUITARY hormones - Abstract
Objective: Studies investigating long-term health conditions in patients with craniopharyngioma are limited by short follow-up durations and generally do not compare long-term health effects according to initial craniopharyngioma treatment approach. In addition, studies comparing long-term health conditions between patients with childhood- and adult-onset craniopharyngioma report conflicting results. The objective of this study was to analyse a full spectrum of long-term health effects in patients with craniopharyngioma according to initial treatment approach and age group at craniopharyngioma presentation. Design: Cross-sectional study based on retrospective data. Methods: We studied a single-centre cohort of 128 patients with craniopharyngioma treated from 1980 onwards (63 patients with childhood-onset disease). Median follow-up since craniopharyngioma presentation was 13 years (interquartile range: 5-23 years). Initial craniopharyngioma treatment approaches included gross total resection (n = 25), subtotal resection without radiotherapy (n = 44), subtotal resection with radiotherapy (n = 25), cyst aspiration without radiotherapy (n = 8), and
90 Yttrium brachytherapy (n = 21). Results: Pituitary hormone deficiencies (98%), visual disturbances (75%) and obesity (56%) were the most common long-term health conditions observed. Different initial craniopharyngioma treatment approaches resulted in similar long-term health effects. Patients with childhood-onset craniopharyngioma experienced significantly more growth hormone deficiency, diabetes insipidus, panhypopituitarism, morbid obesity, epilepsy and psychiatric conditions compared with patients with adult-onset disease. Recurrence-/progression-free survival was significantly lower after initial craniopharyngioma treatment with cyst aspiration compared with other therapeutic approaches. Survival was similar between patients with childhood- and adult-onset craniopharyngioma. Conclusions: Long-term health conditions were comparable after different initial craniopharyngioma treatment approaches and were generally more frequent in patients with childhood- compared with adult-onset disease. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
42. Positive [18F]fluoroethyltyrosine PET/MRI in suspected recurrence of growth hormone–producing pituitary adenoma in a paediatric patient.
- Author
-
Veldhuijzen van Zanten, Sophie E. M., Neggers, Sebastian J. C. M. M., Valkema, Roelf, and Verburg, Frederik A.
- Subjects
PITUITARY cancer ,SOMATOTROPIN ,EMISSION-computed tomography ,MAGNETIC resonance imaging ,AMINO acid transport - Published
- 2021
- Full Text
- View/download PDF
43. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
- Author
-
Neggers, Sebastian J. C. M. M., Pronin, Vyacheslav, Balcere, Inga, Moon-Kyu Lee, Rozhinskaya, Liudmila, Bronstein, Marcello D., Gadelha, Monica R., Maisonobe, Pascal, Sert, Caroline, and van der Lely, Aart Jan
- Subjects
ACROMEGALY ,OCTREOTIDE acetate ,SOMATOSTATIN ,DRUG administration ,ADVERSE health care events - Abstract
Objective: To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg. Design and methods: Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥6 months and had normal IGF1 levels. Lanreotide Autogel 120 mg was administered every 6 weeks for 24 weeks (phase 1); depending on week-24 IGF1 levels, treatment was then administered every 4, 6 or 8 weeks for a further 24 weeks (phase 2). Hormone levels, patient-reported outcomes and adverse events were assessed. Primary endpoint: proportion of patients on 6-or 8-week EDIs with normal IGF1 levels at week 48 (study end). Results: 107/124 patients completed the study (15 withdrew from phase 1 and two from phase 2). Of 124 patients enrolled, 77.4% were allocated to 6- or 8-week EDIs in phase 2 and 75.8% (95% CI: 68.3-83.3) had normal IGF1 levels at week 48 with the EDI (primary analysis). A total of 88.7% (83.1-94.3) had normal IGF1 levels after 24 weeks with 6-weekly dosing. GH levels were ≤2.5 µg/l in >90% of patients after 24 and 48 weeks. Patient preferences for lanreotide Autogel 120 mg every 4, 6 or 8 weeks over octreotide LAR every 4 weeks were high. Conclusions: Patients with acromegaly achieving biochemical control with octreotide LAR 10 or 20 mg/4 weeks are possible candidates for lanreotide Autogel 120 mg EDIs. EDIs are effective and well received among such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults.
- Author
-
Varewijck, Aimee J., Lamberts, Steven W. J., van der Lely, A. J., Neggers, Sebastian J. C. M. M., Hofland, Leo J., and Janssen, Joseph A. M. J. L.
- Subjects
PITUITARY dwarfism ,INSULIN-like growth factor receptors ,HEALTH of adults ,KINASES ,IMMUNOASSAY ,DIAGNOSIS - Abstract
Context: Previously we demonstrated that IGF1 receptor stimulating activity (IGF1RSA) offers advantages in diagnostic evaluation of adult GH deficiency (GHD). It is unknown whether IGF1RSA can be used to monitor GH therapy. Objective: To investigate the value of circulating IGF1RSA for monitoring GH therapy. Design/methods: 106 patients (54 m; 52 f) diagnosed with GHD were included; 22 were GH-naıve, 84 were already on GH treatment and discontinued therapy 4 weeks before baseline values were established. IGF1RSA was determined by the IGF1R kinase receptor activating assay, total IGF1 by immunoassay (Immulite). GH doses were titrated to achieve total IGF1 levels within the normal range. Results: After 12 months, total IGF1 and IGF1RSA increased significantly (total IGF1 from 8.1 (95% CI 7.3-8.9) to 14.9 (95% CI 13.5-16.4) nmol/l and IGF1RSA from 115 (95% CI 104-127) to 181 (95% CI 162-202) pmol/l). After 12 months, total IGF1 normalized in 81% of patients, IGF1RSA in 51% and remained below normal in more than 40% of patients in whom total IGF1 had normalized. Conclusions: During 12 months of GH treatment, changes in IGF1RSA did not parallel changes in total IGF1. Despite normalization of total IGF1, IGF1RSA remained subnormal in a considerable proportion of patients. At present our results have no short-term consequences for GH therapy of GHD patients. However, based on our findings we propose future studies to examine whether titrating GH dose against IGF1RSA results in a better clinical outcome than titrating against total IGF1. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Hypopituitarism after subarachnoid haemorrhage (SAH), do we know enough? A systematic review.
- Author
-
Khajeh, Ladbon, Blijdorp, Karin, Neggers, Sebastian J. C. M. M., Ribbers, Gerard M., Dippel, Diederik W. J., and van Kooten, Fop
- Subjects
HYPOPITUITARISM ,SUBARACHNOID hemorrhage ,SOMATOTROPIN ,GONADOTROPIN ,TESTOSTERONE ,DIABETES insipidus ,QUALITY of life - Abstract
Background Fatigue, slowness, apathy and decrease in level of activity are common long-term complaints after a subarachnoid haemorrhage (SAH). They resemble the symptoms frequently found in patients with endocrine dysfunction. Pituitary dysfunction may be the result of SAH or its complications. We therefore hypothesized that it may explain some of the long-term complaints after SAH. We reviewed the literature to clarify the occurrence, pattern and severity of endocrine abnormalities and we attempted to identify risk factors for hypopituitarism after SAH. We also assessed the effect of hypopituitarism on long-term functional recovery after SAH. Methods In a MEDLINE search for studies published between 1995 and 2014, we used the term subarachnoid haemorrhage in combination with pituitary, hypopituitarism, growth hormone, gonadotropin, testosterone, cortisol function, thyroid function and diabetes insipidus. We selected all case-series and cohort studies reporting endocrine function at least 3 months after SAH and studied their reported prevalence, pathogenesis, risk factors, clinical course and outcome. Results We identified 16 studies describing pituitary function in the long term after SAH. The reported prevalence of endocrine dysfunction varied from 0 to 55% and the affected pituitary axes differed between studies. Due to methodological issues no inferences on risk factors, course and outcome could be made. Conclusions Neuroendocrine dysfunction may be an important and modifiable determinant of poor functional outcome after SAH. There is an urgent need for well-designed prospective studies to more precisely assess its incidence, clinical course and effect on mood, behaviour and quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
46. Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?
- Author
-
özcan, Behiye, Neggers, Sebastian J. C. M. M., Miller, Anne Reifel, Hsiu-Chiung Yang, Lucaites, Virginia, Abribat, Thierry, Allas, Soraya, Huisman, Martin, Visser, Jenny A., Themmen, Axel P. N., Sijbrands, Eric J. G., Delhanty, Patric J. D., and van der Lely, Aart Jan
- Subjects
GHRELIN ,TYPE 2 diabetes ,PROINSULIN ,INSULIN ,PLACEBOS ,HUMAN chromosome 15 abnormalities ,PRADER-Willi syndrome - Abstract
Objective: The objective of this study was to assess the effects of a continuous overnight infusion of des-acyl ghrelin (DAG) on acylated ghrelin (AG) levels and glucose and insulin responses to a standard breakfast meal (SBM) in eight overweight patients with type 2 diabetes. Furthermore, in the same patients and two additional subjects, the effects of DAG infusion on AG concentrations and insulin sensitivity during a hyperinsulinemic-euglycemic clamp (HEC) were assessed. Research design and methods: A double-blind, placebo-controlled cross-over study design was implemented, using overnight continuous infusions of 3 and 10 mg DAG/kg per h and placebo to study the effects on a SBM. During a HEC, we studied the insulin sensitivity. Results: We observed that, compared with placebo, overnight DAG administration significantly decreased postprandial glucose levels, both during continuous glucose monitoring and at peak serum glucose levels. The degree of improvement in glycemia was correlated with baseline plasma AG concentrations. Concurrently, DAG infusion significantly decreased fasting and postprandial AG levels. During the HEC, 2.5 h of DAG infusion markedly decreased AG levels, and the M-index, a measure of insulin sensitivity, was significantly improved in the six subjects in whom we were able to attain steady-state euglycemia. DAG administration was not accompanied by many side effects when compared with placebo. Conclusions: DAG administration improves glycemic control in obese subjects with type 2 diabetes through the suppression of AG levels. DAG is a good candidate for the development of compounds in the treatment of metabolic disorders or other conditions with a disturbed AG:DAG ratio, such as type 2 diabetes mellitus or Prader-Willi syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Abdominal Radiotherapy: A Major Determinant of Metabolic Syndrome in Nephroblastoma and Neuroblastoma Survivors.
- Author
-
van Waas, Marjolein, Neggers, Sebastian J. C. M. M., Raat, Hein, van Rij, Caroline M., Pieters, Rob, and van den Heuvel-Eibrink, Marry M.
- Subjects
NEUROBLASTOMA ,BIOCHEMISTRY ,MEDICAL radiology ,MEDICAL physics ,RADIATION - Abstract
Background: Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome. Patients and Methods: In this prospective study 164 subjects participated (67 adult long-term nephroblastoma survivors (28 females), 36 adult long-term neuroblastoma survivors (21 females) and 61 control subjects (28 females)). Controls were recruited cross-sectionally. Waist and hip circumference as well as blood pressure were measured. Body composition and abdominal fat were assessed by dual energy X-ray absorptiometry (DXA-scan). Laboratory measurements included fasting triglyceride, high density lipoprotein-cholesterol (HDL-C), glucose, insulin, low-density lipoprotein-cholesterol (LDL-C) and free fatty acids (FFA) levels. Results: Median age at follow-up was 30 (range 19-51) years in survivors and 32 (range 18-62) years in controls. Median follow-up time in survivors was 26 (6-49) years. Nephroblastoma (OR = 5.2, P,0.0001) and neuroblastoma (OR 6.5, P,0.001) survivors had more components of the metabolic syndrome than controls. Survivors treated with abdominal irradiation had higher blood pressure, triglycerides, LDL-C, FFA and lower waist circumference. The latter can not be regarded as a reliable factor in these survivors as radiation affects the waist circumference. When total fat percentage was used as a surrogate marker of adiposity the metabolic syndrome was three times more frequent in abdominally irradiated survivors (27.5%) than in non-irradiated survivors (9.1%, P = 0.018). Conclusions: Nephroblastoma and neuroblastoma survivors are at increased risk for developing components of metabolic syndrome, especially after abdominal irradiation. We emphasize that survivors treated with abdominal irradiation need alternative adiposity measurements for assessment of metabolic syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
48. Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer.
- Author
-
Blijdorp, Karin, van den Heuvel-Eibrink, Marry M., Pieters, Rob, Boot, Annemieke M., Delhanty, Patric J. D., van der Lely, Aart-Jan, Neggers, Sebastian J. C. M. M., and de Mello, Ramon Andrade
- Subjects
OBESITY ,BODY mass index ,THERAPEUTIC complications ,CANCER treatment ,HUMAN body composition ,BODY weight - Abstract
Objective: Obesity, represented by high body mass index (BMI), is a major complication after treatment for childhood cancer. However, it has been shown that high total fat percentage and low lean body mass are more reliable predictors of cardiovascular morbidity. In this study longitudinal changes of BMI and body composition, as well as the value of BMI and waist-hip ratio representing obesity, were evaluated in adult childhood cancer survivors. Methods: Data from 410 survivors who had visited the late effects clinic twice were analyzed. Median follow-up time was 16 years (interquartile range 11-21) and time between visits was 3.2 years (2.9-3.6). BMI was measured and body composition was assessed by dual X-ray absorptiometry (DXA, Lunar Prodigy; available twice in 182 survivors). Data were compared with healthy Dutch references and calculated as standard deviation scores (SDS). BMI, waist-hip ratio and total fat percentage were evaluated cross-sectionally in 422 survivors, in who at least one DXA scan was assessed. Results: BMI was significantly higher in women, without significant change over time. In men BMI changed significantly with time (ΔSDS = 0.19, P<0.001). Percentage fat was significantly higher than references in all survivors, with the highest SDS after cranial radiotherapy (CRT) (mean SDS 1.73 in men, 1.48 in women, P<0.001). Only in men, increase in total fat percentage was significantly higher than references (ΔSDS = 0.22, P<0.001). Using total fat percentage as the gold standard, 65% of female and 42% of male survivors were misclassified as non- obese using BMI. Misclassification of obesity using waist-hip ratio was 40% in women and 24% in men. Conclusions: Sixteen years after treatment for childhood cancer, the increase in BMI and total fat percentage was significantly greater than expected, especially after CRT. This is important as we could show that obesity was grossly underestimated using BMI and waist-hip ratio. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
49. Response to inquiry by Gaylinn et al. on 'Administration of UAG improves glycemic control in obese subjects with diabetes'.
- Author
-
özcan, Behiye, Neggers, Sebastian J. C. M. M., Miller, Anne Reifel, Hsiu-Chiung Yang, Lucaites, Virginia, Abribat, Thierry, Allas, Soraya, Huisman, Martin, Visser, Jenny A., Themmen, Axel P. N., Sijbrands, Eric J. G., Delhanty, Patric J. D., and van der Lely, Aart Jan
- Subjects
GHRELIN ,GLYCEMIC index ,THERAPEUTICS - Abstract
A response from the author of the article related to controlling of glycemic by administrating unacylated ghrelin (UAG) in obese subjects with diabetes in a previous issue of the periodical.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.